MCID: LMN006
MIFTS: 37

Luminal Breast Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Luminal Breast Carcinoma

MalaCards integrated aliases for Luminal Breast Carcinoma:

Name: Luminal Breast Carcinoma 12 14
Luminal Breast Cancer 12
Breast Tumor Luminal 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060548

Summaries for Luminal Breast Carcinoma

MalaCards based summary : Luminal Breast Carcinoma, also known as luminal breast cancer, is related to ductal carcinoma in situ and bartholin's gland benign neoplasm. An important gene associated with Luminal Breast Carcinoma is MTOR (Mechanistic Target Of Rapamycin), and among its related pathways/superpathways are Downstream signaling events of B Cell Receptor (BCR) and MicroRNAs in cancer. The drugs Letrozole and Vitamin D have been mentioned in the context of this disorder. Affiliated tissues include breast and bone, and related phenotypes are Decreased viability and growth/size/body region

Related Diseases for Luminal Breast Carcinoma

Diseases related to Luminal Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
id Related Disease Score Top Affiliating Genes
1 ductal carcinoma in situ 29.0 EGFR ERBB2 ESR1 KRT5 PGR
2 bartholin's gland benign neoplasm 10.7 ESR1 PGR
3 central nervous system organ benign neoplasm 10.7 ESR1 PGR
4 nerve fibre bundle defect 10.7 ERBB2 ESR1
5 gallbladder leiomyoma 10.7 ESR1 PGR
6 gastritis 10.7 ERBB2 PGR
7 lung adenoma 10.7 ESR1 PGR
8 fallopian tube benign neoplasm 10.7 ESR1 PGR
9 paranasal sinus disease 10.7 ESR1 PGR
10 dartoic leiomyoma 10.7 ESR1 PGR
11 infiltrating ureter transitional cell carcinoma 10.7 EGFR ERBB2
12 urinary bladder inverted papilloma 10.7 ESR1 PGR
13 deafness, autosomal dominant 8/12 10.7 ESR1 PGR
14 severe pre-eclampsia 10.7 EGFR MTOR
15 superficial basal cell carcinoma 10.7 ESR1 PGR
16 sarcomatoid squamous cell skin carcinoma 10.7 ESR1 PGR
17 bladder colloid adenocarcinoma 10.6 ESR1 PGR
18 ovarian mesodermal adenosarcoma 10.6 ESR1 PGR
19 endophthalmitis 10.6 ESR1 PGR
20 osteogenesis imperfecta 10.6 ESR1 PGR
21 chest wall lymphoma 10.6 ESR1 PGR
22 brenner tumor of the vagina 10.6 ERBB2 ESR1
23 kallmann syndrome 10.6 ERBB2 PGR
24 colon neuroendocrine neoplasm 10.6 ERBB2 PGR
25 cutaneous mucoepidermoid carcinoma 10.6 ESR1 PGR
26 retinal detachment 10.6 ESR1 PGR
27 brenner tumor of ovary 10.6 ERBB2 ESR1
28 holoprosencephaly 6 10.6 ESR1 PGR
29 acute thyroiditis 10.5 ESR1 PGR
30 breast cancer 10.5
31 kidney leiomyosarcoma 10.5 ERBB3 PGR
32 glaucoma, hereditary 10.5 ERBB2 ESR1 PGR
33 spinal cancer 10.5 ERBB2 ESR1 PGR
34 gangliosidosis gm2 10.5 ESR1 MTOR PGR
35 acantholytic acanthoma 10.5 KRT5 MTOR
36 her2-receptor positive breast cancer 10.5 ERBB2 ESR1 PGR
37 bladder tuberculosis 10.5 ERBB2 KRT5
38 retinitis pigmentosa 20 10.5 ESR1 PGR
39 organ system benign neoplasm 10.5 ERBB2 ESR1 PGR
40 cartilage cancer 10.5 ERBB2 ESR1 PGR
41 cell type benign neoplasm 10.5 ERBB2 ESR1 PGR
42 fallopian tube carcinosarcoma 10.5 ERBB2 ESR1 PGR
43 breast duct papilloma 10.5 ERBB2 ESR1 PGR
44 congenital heart defects and skeletal malformations syndrome 10.5 ESR1 MTOR PGR
45 mixed cerebral palsy 10.5 ERBB2 ESR1 PGR
46 trachea carcinoma in situ 10.4 ERBB2 ESR1 PGR
47 early congenital syphilis 10.4 EGFR ERBB2 MTOR
48 childhood ovarian embryonal carcinoma 10.4 ERBB2 ESR1 PGR
49 otitis externa 10.4 ERBB2 PGR
50 breast sarcoma 10.4 ERBB2 ESR1

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma:



Diseases related to Luminal Breast Carcinoma

Symptoms & Phenotypes for Luminal Breast Carcinoma

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.93 MTOR EGFR
2 Decreased viability GR00106-A-0 9.93 ERBB3
3 Decreased viability GR00221-A-1 9.93 ESR1 MTOR EGFR
4 Decreased viability GR00221-A-2 9.93 ESR1 ERBB3
5 Decreased viability GR00221-A-3 9.93 ERBB2
6 Decreased viability GR00221-A-4 9.93 ESR1 MTOR EGFR ERBB2 ERBB3
7 Decreased viability GR00301-A 9.93 ERBB3
8 Decreased viability GR00342-S-1 9.93 MTOR
9 Decreased viability GR00342-S-2 9.93 MTOR ERBB3
10 Decreased viability GR00342-S-3 9.93 ERBB3
11 Decreased substrate adherent cell growth GR00193-A-1 9.46 ERBB3
12 Decreased substrate adherent cell growth GR00193-A-2 9.46 EGFR ERBB3 MTOR
13 Decreased viability with paclitaxel GR00179-A-1 9.36 EGFR MTOR ERBB2
14 Decreased viability with paclitaxel GR00179-A-2 9.36 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.36 EGFR MTOR

MGI Mouse Phenotypes related to Luminal Breast Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.02 EGFR ERBB2 ERBB3 ESR1 FOXA1 GATA3
2 endocrine/exocrine gland MP:0005379 10.01 EGFR ERBB2 ERBB3 ESR1 FOXA1 GATA3
3 digestive/alimentary MP:0005381 10 EGFR ERBB2 ERBB3 ESR1 FOXA1 GATA3
4 embryo MP:0005380 9.98 EGFR ERBB2 ERBB3 ESR1 GATA3 MTOR
5 integument MP:0010771 9.92 EGFR ERBB2 ERBB3 ESR1 FOXA1 GATA3
6 muscle MP:0005369 9.8 EGFR ERBB2 ERBB3 ESR1 GATA3 MTOR
7 neoplasm MP:0002006 9.63 EGFR ERBB2 ERBB3 ESR1 FOXA1 PGR
8 no phenotypic analysis MP:0003012 9.43 EGFR ESR1 GATA3 KRT5 MTOR PGR
9 normal MP:0002873 9.17 ERBB2 ERBB3 ESR1 GATA3 MTOR PGR

Drugs & Therapeutics for Luminal Breast Carcinoma

Drugs for Luminal Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 112809-51-5 3902
2
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
3 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
4 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
5 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
6 Estrogens Phase 4,Phase 3,Phase 2,Early Phase 1
7 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
8 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
9 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
10 Calcium, Dietary Phase 4
11
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
12
Phenobarbital Approved Phase 3,Phase 2 50-06-6 4763
13
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
14
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
15
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
16
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
17
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
18
Gemcitabine Approved Phase 3 95058-81-4 60750
19
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
20
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
21
Vinorelbine Approved, Investigational Phase 3,Early Phase 1 71486-22-1 60780 44424639
22
Fluorouracil Approved Phase 3 51-21-8 3385
23
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
24 Anticonvulsants Phase 3,Phase 2
25 Central Nervous System Depressants Phase 3,Phase 2
26 Cytochrome P-450 CYP3A Inducers Phase 3,Phase 2
27 Excitatory Amino Acid Antagonists Phase 3,Phase 2
28 Excitatory Amino Acids Phase 3,Phase 2
29 GABA Agents Phase 3,Phase 2
30 GABA Modulators Phase 3,Phase 2
31 Hypnotics and Sedatives Phase 3,Phase 2
32 Neurotransmitter Agents Phase 3,Phase 2
33 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Early Phase 1
34 Albumin-Bound Paclitaxel Phase 3,Phase 2
35 Antimitotic Agents Phase 3,Phase 2,Early Phase 1
36 Anti-Infective Agents Phase 3
37 Antimetabolites Phase 3
38 Antimetabolites, Antineoplastic Phase 3
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2
40 Antiviral Agents Phase 3
41 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
42 Estrogen Receptor Modulators Phase 3,Phase 2
43 Immunosuppressive Agents Phase 3,Phase 2
44 Selective Estrogen Receptor Modulators Phase 3,Phase 2
45 taxane Phase 3,Phase 1,Phase 2
46 Tin Fluorides Phase 3
47 Alkylating Agents Phase 3,Phase 2
48 Anti-Bacterial Agents Phase 3,Phase 2
49 Antibiotics, Antitubercular Phase 3,Phase 2
50 Antirheumatic Agents Phase 3,Phase 2

Interventional clinical trials:

(show all 40)

id Name Status NCT ID Phase Drugs
1 HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer Not yet recruiting NCT03111615 Phase 4 Aromatase Inhibitors
2 Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer Recruiting NCT01950182 Phase 3 Endocrine therapy combined with trastuzumab;Chemotherapy combined with trastuzumab
3 CHemo-ENDOcrine Therapy in Advanced Breast Cancer Recruiting NCT03227328 Phase 3 concomitant chemotherapy plus an aromatase inhibitor (AI);chemotherapy followed by an aromatase inhibitor (AI)
4 Efficacy Study of Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients Active, not recruiting NCT01314833 Phase 3 Docetaxel Cyclophosphamide;Cyclophosphamide Fluorouracil Epirubicin Docetaxel;Epirubicin Cyclophosphamide Paclitaxel
5 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients Unknown status NCT00432172 Phase 2 Standard treatment;Selective treatment;Standard treatment;Selective treatment
6 Breast Cancer - Anti-Progestin Prevention Study 1 Unknown status NCT02408770 Phase 2 ulipristal acetate
7 Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) Completed NCT01779479 Phase 2 Cabacitaxel;Paclitaxel
8 Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer Completed NCT01431196 Phase 2
9 Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer Completed NCT01669252 Phase 2 Eribulin
10 Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. Recruiting NCT03248427 Phase 2 Ribociclib;Letrozole 2.5mg;Doxorubicin;Cyclophosphamide;Paclitaxel
11 Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone Recruiting NCT02806258 Phase 1, Phase 2 Chemotherapy
12 Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases Recruiting NCT02603679 Phase 2 Paclitaxel;Tamoxifen + Palbociclib;Aromatase Inhibitor + Palbociclib;Goserelin + Aromatase Inhibitor + Palbociclib
13 Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy Recruiting NCT03094052 Phase 2 Neratinib;Trastuzumab;Crofelemer;Loperamide
14 A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers Recruiting NCT02238808 Phase 2 Estradiol
15 Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors Recruiting NCT02592083 Phase 2 Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin;Palbociclib
16 Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer Recruiting NCT02041338 Phase 2 Paclitaxel and carboplatin;Paclitaxel;Epirubicin and Paclitaxel
17 Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer Active, not recruiting NCT01565499 Phase 2 Nab-paclitaxel
18 Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women Active, not recruiting NCT02400567 Phase 2 Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
19 Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Active, not recruiting NCT02213042 Phase 2 Lapatinib
20 Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. Not yet recruiting NCT03283384 Phase 2 Letrozole;Chemotherapy;Ribociclib plus letrozole
21 Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC Withdrawn NCT02140437 Phase 2 Fulvestrant;Anastrozole
22 A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) Completed NCT00759785 Phase 1 dalotuzumab (MK0646)
23 Pilot Study of Bisphosphonates for Breast Cancer Recruiting NCT02781805 Phase 1 Alendronate
24 Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients Unknown status NCT01779531
25 Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments Unknown status NCT02284581
26 Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM" Completed NCT02244580
27 Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy Completed NCT02449993
28 Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer Completed NCT01273415
29 Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis Completed NCT01377363
30 Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy Completed NCT00911911
31 Comparison of the Breast Tumor Microenvironment Recruiting NCT03165487
32 EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer Recruiting NCT02889874
33 CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages. Recruiting NCT01984866
34 Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA) Recruiting NCT02802748 Early Phase 1 Oral Vinorelbine;Letrozole
35 Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer Recruiting NCT01560663 Docetaxel- Carboplatin
36 A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) Recruiting NCT02819882
37 Observation of Medical Treatments in MBC HER2-negative Patients Recruiting NCT02365831
38 A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer Active, not recruiting NCT01791829
39 From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspectives in Breast Cancers Not yet recruiting NCT02863900
40 Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients Not yet recruiting NCT03197805

Search NIH Clinical Center for Luminal Breast Carcinoma

Genetic Tests for Luminal Breast Carcinoma

Anatomical Context for Luminal Breast Carcinoma

MalaCards organs/tissues related to Luminal Breast Carcinoma:

39
Breast, Bone

Publications for Luminal Breast Carcinoma

Articles related to Luminal Breast Carcinoma:

id Title Authors Year
1
Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. ( 27511992 )
2016
2
p-mTOR expression is associated with better prognosis in luminal breast carcinoma. ( 25053543 )
2014
3
Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas. ( 23754601 )
2013
4
Her2 negative luminal breast carcinoma and Ki-67 evaluation. ( 22647834 )
2012

Variations for Luminal Breast Carcinoma

Expression for Luminal Breast Carcinoma

Search GEO for disease gene expression data for Luminal Breast Carcinoma.

Pathways for Luminal Breast Carcinoma

Pathways related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 EGFR ERBB2 ERBB3 MTOR
2 12.34 EGFR ERBB2 ERBB3 MTOR
3
Show member pathways
12.32 EGFR ERBB2 ERBB3 MTOR
4
Show member pathways
12.31 EGFR ERBB2 ERBB3 MTOR
5
Show member pathways
12.29 ELF5 ERBB2 ESR1 MTOR
6
Show member pathways
12.29 EGFR ERBB2 ERBB3 ESR1 MTOR PGR
7
Show member pathways
12.25 EGFR ERBB2 ERBB3 MTOR
8
Show member pathways
12.07 EGFR ERBB2 ERBB3 MTOR
9
Show member pathways
12.05 EGFR ERBB2 ERBB3 MTOR
10
Show member pathways
12.03 EGFR ERBB2 ERBB3 ESR1
11 12.02 EGFR ERBB2 MTOR
12 11.99 EGFR ESR1 MTOR
13
Show member pathways
11.95 EGFR ERBB2 MTOR
14 11.93 EGFR ERBB2 ERBB3
15
Show member pathways
11.9 EGFR ERBB2 ERBB3
16
Show member pathways
11.86 EGFR ERBB2 ERBB3
17 11.76 EGFR ERBB2 MTOR
18
Show member pathways
11.72 EGFR ERBB2 ESR1
19 11.66 EGFR ERBB2 ERBB3 ESR1 MTOR
20 11.49 EGFR ESR1 MTOR
21 11.47 EGFR ERBB2 MTOR
22 11.29 EGFR ERBB2 ERBB3
23 11.15 EGFR ERBB2 ERBB3
24
Show member pathways
11.05 EGFR MTOR
25
Show member pathways
11.05 EGFR ERBB2 ERBB3 ESR1 PGR
26 10.92 EGFR ERBB2 ERBB3
27 10.81 EGFR ERBB2 MTOR

GO Terms for Luminal Breast Carcinoma

Cellular components related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.8 EGFR ERBB2 ERBB3

Biological processes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.93 EGFR ELF5 ESR1 FOXA1 GATA3 PGR
2 positive regulation of gene expression GO:0010628 9.9 ERBB2 ERBB3 GATA3 MTOR
3 peptidyl-tyrosine phosphorylation GO:0018108 9.8 EGFR ERBB2 ERBB3
4 positive regulation of protein phosphorylation GO:0001934 9.79 EGFR ERBB2 MTOR
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.75 EGFR ERBB2 ERBB3
6 phosphatidylinositol phosphorylation GO:0046854 9.72 EGFR ERBB2 ERBB3
7 response to estradiol GO:0032355 9.71 EGFR ESR1 FOXA1
8 positive regulation of protein kinase B signaling GO:0051897 9.7 EGFR GATA3 MTOR
9 chromatin remodeling GO:0006338 9.67 ESR1 FOXA1 GATA3
10 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.65 EGFR ERBB2 ERBB3
11 regulation of transcription from RNA polymerase II promoter GO:0006357 9.63 EGFR ELF5 ERBB2 ESR1 FOXA1 GATA3
12 peripheral nervous system development GO:0007422 9.61 ERBB2 ERBB3
13 anatomical structure formation involved in morphogenesis GO:0048646 9.61 FOXA1 GATA3
14 cellular response to estradiol stimulus GO:0071392 9.61 EGFR ESR1 ZNF703
15 uterus development GO:0060065 9.58 ESR1 GATA3
16 ERBB2 signaling pathway GO:0038128 9.58 EGFR ERBB2 ERBB3
17 TOR signaling GO:0031929 9.57 GATA3 MTOR
18 mammary gland epithelial cell differentiation GO:0060644 9.56 ELF5 ZNF703
19 phosphatidylinositol-mediated signaling GO:0048015 9.56 EGFR ERBB2 ERBB3 MTOR
20 phosphatidylinositol 3-kinase signaling GO:0014065 9.54 ERBB2 ERBB3 GATA3
21 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.51 ERBB2 MTOR
22 regulation of cell motility GO:2000145 9.5 EGFR ERBB2 ERBB3
23 wound healing GO:0042060 9.26 EGFR ERBB2 ERBB3 MTOR
24 negative regulation of ERBB signaling pathway GO:1901185 8.8 EGFR ERBB2 ERBB3
25 signal transduction GO:0007165 10.14 EGFR ERBB2 ERBB3 ESR1 GATA3 MTOR

Molecular functions related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.76 EGFR ERBB2 ERBB3 MTOR
2 enzyme binding GO:0019899 9.73 EGFR ESR1 PGR PREX1
3 protein tyrosine kinase activity GO:0004713 9.67 EGFR ERBB2 ERBB3
4 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.67 ESR1 FOXA1 GATA3 PGR
5 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 9.65 ELF5 FOXA1 GATA3
6 sequence-specific DNA binding GO:0043565 9.65 ELF5 ESR1 FOXA1 GATA3 PGR
7 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 EGFR ERBB2 ERBB3
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.33 EGFR ERBB2 ERBB3
9 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.32 EGFR ERBB2
10 nitric-oxide synthase regulator activity GO:0030235 8.96 EGFR ESR1
11 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 EGFR ERBB2 ERBB3

Sources for Luminal Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....